INTERRELATION OF THE EXPRESSION OF PROTEINS ALK, HER2 AND AMPLIFICATION OF THE GENE OF HER2 WITH THE PROLIFERATIVE ACTIVITY AND SURVIVAL IN PATIENTS WITH STAGE I-II LUNG ADENOCARCINOMA

Abstract

To investigate protein content of ALK, Her2 and gene of Her2, CEP17 in interrelation with proliferative activity and survival in I-II stages lung adenocarcinoma cases. There were investigated 82 surgery samples taken from I-II stage lung adenocarcinoma patients. With the use of immunohistochemical method ALK protein (clone D5F3, Ventana), Her2 protein (clone 4B5, Ventana), topoizomerase IIα (clone JS5B4, Ventana), Ki-67 (clone MIB-1, Dako) were determined, Her2 gene was investigated with the use of the SISH method (Ventana) also. The positive expression of ALK is detected in 4(5%) cases, Her2 - in 16(20%) cases and amplification of Her2 gene - in 7(9%) cases. In lung adenocarcinoma with positive expression of ALK protein and amplification of Her2 gene low proliferative activity was noted (on labeling index Ki-67 and topoizomerase IIα). The survival of lung adenocarcinoma patients was less in cases of a positive expression of ALK protein in comparison with patients with the negative expression (difference is not reliable). Statistically significant low survival rates of patients is found in cases with amplification of Her2 gene. According to data mono- and multifactor regression analysis the amplification of Her2 gene has been interrelated with the poor forecast. Mutation of ALK gene and amplification of Her2 gene are interrelated with the proliferative activity and survival rate of lung adenocarcinoma patients.